Bertrand Drugeon

Chlorhexidine plus alcohol versus povidone iodine plus alcohol, combined or not with innovative devices, for prevention of short-term peripheral venous catheter infection and failure (CLEAN 3 study): an investigator-initiated, open-label, single centre, randomised-controlled, two-by-two factorial trial

Jérémy Guénézan, Nicolas Marjanovic, Bertrand Drugeon et al. · The Lancet Infectious Diseases · 2021 · 61 citations · Full text

Venous Disease, Clean 3, Antibiotics +8

Incidence, complications, and costs of peripheral venous catheter-related bacteraemia: a retrospective, single-centre study

Bertrand Drugeon, Jérémy Guénézan, Maxime Pichon et al. · Journal of Hospital Infection · 2023 · 42 citations · Full text

Venous Disease, Healthcare-associated Infection, Clinical Epidemiology +9

Ferric derisomaltose and tranexamic acid, combined or alone, for reducing blood transfusion in patients with hip fracture (the HiFIT trial): a multicentre, 2 × 2 factorial, randomised, double-blind, controlled trial

Sigismond Lasocki, Xavier Capdevila, Bruno Vielle et al. · The Lancet Haematology · 2023 · 25 citations

Transfusion Medicine, Hematology, Clinical Trials +8

Skin antisepsis with chlorhexidine–alcohol versus povidone iodine–alcohol, combined or not with use of a bundle of new devices, for prevention of short-term peripheral venous catheter-related infectious complications and catheter failure: an open-label, single-centre, randomised, four-parallel group, two-by-two factorial trial: CLEAN 3 protocol study

Jérémy Guénézan, Bertrand Drugeon, Rodérick O’Neill et al. · BMJ Open · 2019 · 14 citations · Full text

Cost-effectiveness analysis of bundled innovative devices versus standard approach in the prevention of unscheduled peripheral venous catheters removal due to complications in France

Franck Maunoury, Bertrand Drugeon, Matthieu Boisson et al. · PLoS ONE · 2022 · 12 citations · Full text